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MaBACKGROUND Patients with type 1 diabetes mellitus (T1DM) have a high risk of cardiovascular events.
OBJECTIVES The aim of this study was to investigate whether preoperative hemoglobin A1c (HbA1c) levels could predict
cardiovascular events or death after coronary artery bypass grafting (CABG).
METHODS This was a nationwide population-based observational cohort study that included all patients with
T1DM who underwent primary isolated nonemergency CABG in Sweden between 1997 and 2012, according to the
Swedish National Diabetes Register and the SWEDEHEART (Swedish Web-system for Enhancement and Develop-
ment of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register. We
calculated the crude incidence rates and 95% conﬁdence intervals (CIs) and used Cox regression and multivariable
hazard ratios (HRs) to estimate the risk of both all-cause mortality and major adverse cardiovascular events
(MACE), deﬁned as myocardial infarction, stroke, heart failure, or repeat revascularization, in relation to
HbA1c levels.
RESULTS In total, 764 patients with T1DM were included. During a median follow-up of 4.7 years, 334 (44%) patients
died or had MACE (incidence rate: 82 events/1,000 person-years). After multivariable adjustment, the HR (95% CI)
for death or MACE in patients with HbA1c levels of 7.1% to 8.0%, 8.1% to 9.0%, 9.1% to 10.0%, and >10.0% were
1.34 (0.82 to 2.21), 1.59 (1.00 to 2.54), 1.73 (1.03 to 2.90), and 2.25 (1.29 to 3.94), respectively, compared with
the reference category. When HbA1c was used as a continuous variable, the HR for a 1% increase in HbA1c level was 1.18,
and the 95% CI was 1.06 to 1.32.
CONCLUSIONS In patients with T1DM, poor glycemic control before CABG was associated with increased
long-term risk of death or MACE. (HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery [HARTROCS];
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
grafting
CHD = coronary heart disease
CVD = cardiovascular disease
HbA1c = hemoglobin A1c
MACE = major adverse
cardiovascular event(s)
T1DM = type 1 diabetes
mellitus
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536A dvances in treatment for type 1 dia-betes mellitus (T1DM) have improvedlife expectancy and decreased mor-
tality rates over time (1). Despite declining
rates of diabetes-associated complications in
the past 2 decades (2), the disease persists in
large numbers, and the prevalence of cardio-
vascular disease (CVD), the most common
complication among patients with diabetes,
remains very high (3). Abnormal vascular
ﬁndings associated with atherosclerosis are
much more common in patients with T1DMcompared with nondiabetic patients (4). The risk of
CVD events is high and occurs earlier in patients
with T1DM; incidence rates of deaths, even in patients
with T1DM who have good glycemic control, are
reached at a much younger age compared with the
general population (5,6).SEE PAGE 544Revascularization surgery for patients with multi-
vessel coronary heart disease (CHD) is a common
procedure; approximately 25% of these patients have
diabetes. Patients with diabetes and established CHD
often have more complicated atherosclerosis and are
at higher risk of developing major adverse CVD events
and death than are patients without diabetes (7–10).
Revascularization studies have evaluated patients on
the basis of various categorizations, including the
presence or absence of diabetes (8,9) and the pres-
ence of insulin-dependent or not insulin-dependent
diabetes (7). In patients with T1DM and CHD, the as-
sociation between glycemic control and cardiovas-
cular outcomes after revascularization remains
unclear (11). Because patients with T1DM have a high
risk of CVD events and death (5), we wanted to
investigate whether different levels of glycemic con-
trol could predict CVD events after coronary artery
bypass graft (CABG) procedures in these patients.
The aim of this study was to analyze the associa-
tion between preoperative hemoglobin A1c (HbA1c)
levels and combined all-cause mortality and
myocardial infarction, heart failure, stroke, or repeat
revascularization in patients with T1DM who were
undergoing primary isolated nonemergency CABG.
METHODS
STUDY DESIGN. This was an observational nation-
wide population-based cohort study. The study was
approved by the regional Human Research Ethics
Committee, Stockholm, Sweden.
STUDY POPULATION. The study population was
obtained by cross-referencing patient-level datafrom the SWEDEHEART (Swedish Web-system for
Enhancement and Development of Evidence-based
care in Heart disease Evaluated According to Rec-
ommended Therapies) register (12) and the National
Diabetes Register (13). All patients with T1DM (ac-
cording to the Swedish National Diabetes Register)
who underwent primary isolated nonemergency
CABG in Sweden between 1997 and 2012 were in-
cluded. Further information regarding baseline char-
acteristics was extracted from the National Patient
Register. Cross-referencing was possible through the
unique personal identity number assigned to every
Swedish citizen (14). The epidemiological deﬁnition
of T1DM in the Swedish National Diabetes Register is
onset of diabetes before the age of 30 years and
treatment with insulin only (13).
HEMOGLOBIN A1C. Analyses of HbA1c were carried
out at local laboratories with the high-performance
liquid chromatography Mono-S method and were
quality assured nationwide by regular calibration. We
converted all HbA1c values to standard values ac-
cording to the National Glycohemoglobin Standardi-
zation Program (15). We calculated the mean of all
available HbA1c values before the date of CABG for
each patient (16). On the basis of their preoperative
mean HbA1c values, patients were assigned to 1 of the
following HbA1c categories: #7.0%, 7.1% to 8.0%,
8.1% to 9.0%, 9.1% to 10.0%, and >10.0%.
OUTCOMES. The primary outcome measure was a
combination of all-cause mortality and major adverse
cardiovascular event (MACE), deﬁned as rehospitali-
zation for a primary diagnosis of myocardial infarc-
tion (International Classiﬁcation of Diseases-Tenth
Revision [ICD-10] codes: I21 to I21.9), heart failure
(ICD-10 codes: I50 to I50.9), stroke (ICD-10 codes: I60
to I69.9), or repeat revascularization (ICD-10 codes:
FNG, FNA, FNC). The date and cause of death were
obtained from the national Cause of Death Register;
the date and cause of rehospitalization were obtained
from the National Patient Register. The validity of the
diagnoses of myocardial infarction, heart failure, and
stroke has been evaluated in the National Patient
Register and found to be 95% for a primary diagnosis
of heart failure; the positive predictive value is 98%
to 100% for myocardial infarction and 98.6% for
stroke (17,18). We also assessed death from cardio-
vascular and noncardiovascular causes separately.
Finally, the following ICD-10 codes were used to
analyze hospitalizations for hypoglycemia: E10.0,
E10.6, and E16 to E16.2.
MISSING DATA. We excluded patients with missing
information regarding preoperative HbA1c. For the
following variables that were used as covariates in the
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537multivariable analyses, some data were missing: renal
function (7.5%), number of bypass grafts (11%), and
left ventricular ejection fraction (34%). We used
multiple imputation by chained equations to handle
missing data (19). The imputation models included 26
variables, including the event indicator and the
Nelson-Aalen estimator of the cumulative baseline
hazard (20), under the assumption that the missing
values were missing at random. Twenty-ﬁve datasets
were imputed, and estimates from these datasets
were combined according to Rubin’s rules.
STATISTICAL METHODS. Patients’ characteristics
were described using frequencies and percentages for
categorical variables and using means and standard
deviations for continuous variables. The primary
outcome measure was death from any cause or hos-
pitalization for a MACE (myocardial infarction, heart
failure, stroke, or repeat revascularization). Patients
contributed person-time in days from the date of the
surgical procedure until the date of death from any
cause, the date of a MACE, or at the end of the follow-
up period (December 31, 2012), whichever occurred
ﬁrst. We calculated the crude incidence rates and 95%
conﬁdence intervals (CIs). We used Cox regression to
estimate the risk of the combined endpoint all-cause
mortality or myocardial infarction, heart failure,
stroke, or repeat revascularization according to the
following preoperative HbA1c categories: 7.1% to
8.0%, 8.1% to 9.0%, 9.1% to 10.0%, and >10.0%, by
using HbA1c #7.0% as the reference level. We calcu-
lated crude age- and sex-adjusted and multivariable
adjusted hazard ratios (HRs) and 95% CIs. All vari-
ables listed in Table 1 were included as covariates in
the ﬁnal multivariable model. We investigated the
potential nonlinear relationship between HbA1c and
outcome in a Cox model, where HbA1c was modeled
by restricted cubic splines, and adjusted HRs and 95%
CIs were plotted against HbA1c levels. We investi-
gated differences in each cause of mortality (cardio-
vascular death or noncardiovascular causes) by
competing risk regression on the basis of the Fine-
Gray proportional subhazards model (21), and we
calculated subdistribution HRs and 95% CIs. Data
management and statistical analyses were performed
using Stata version 13.1 (Stata Corp., College Station,
Texas) and R version 3.1.2 (R Foundation for Statis-
tical Computing, Vienna, Austria).
RESULTS
Baseline patient characteristics are presented in
Table 1. The study population included 764 patients,
and during a median follow-up time of 4.7 years
(interquartile range [IQR]: 1.8 to 8.8 years), 334 (44%)patients died or had a MACE, for an incidence rate of
82 events per 1,000 person-years (95% CI: 73 to 91).
The mean age was highest in the lowest HbA1c cate-
gory, and the mean age decreased with increasing
preoperative HbA1c level. The proportion of women
was highest among those with very poor glycemic
control (HbA1c >10.0%). Early mortality (death within
30 days of the surgical procedure) was 4 of 67 (5.6%),
2 of 190 (1.1%), 5 of 296 (1.7%), 2 of 146 (1.4%), and
1 of 65 (1.5%), in the low to high HbA1c categories,
respectively.
The age-adjusted freedom from death or MACE is
shown in Figure 1. The crude incidence of death or
MACE in patients with preoperative HbA1c
levels #7.0%, 7.1% to 8.0%, 8.1% to 9.0%, 9.1% to
10.0%, and >10.0% was 81 (95% CI: 56 to 116), 76
(95% CI: 61 to 96), 77 (95% CI: 64 to 92), 80 (95% CI:
63 to 103), and 121 (95% CI: 90 to 163) per 1,000
person-years, respectively (Table 2).
No signiﬁcant association was observed between
preoperative HbA1c level and death or MACE in the
unadjusted analyses (Table 2). After adjustment for
age and sex, patients with high HbA1c levels (i.e., poor
glycemic control) had a signiﬁcantly higher risk of
death or MACE compared with patients with low
HbA1c levels (#7.0%).
After multivariable adjustment, the HR (95% CI) for
death or MACE was 1.34 (0.82 to 2.21) in patients with
HbA1c from 7.1% to 8.0%, 1.59 (1.00 to 2.54) in patients
with HbA1c from 8.1% to 9.0%, 1.73 (1.03 to 2.90) in
patients with HbA1c from 9.1% to 10.0%, and 2.25
(1.29 to 3.94) in patients with HbA1c >10.0% compared
with patients with low HbA1c levels (#7.0%), as
shown in Table 2 and the Central Illustration.
The numbers of patients who were hospitalized at
least once for hypoglycemia after CABG were 7 of 67
(10%), 15 of 190 (7.9%), 24 of 296 (8.1%), 19 of 146
(13%), and 11 of 65 (17%) in the low to high HbA1c
categories, respectively.
DEATH FROM CARDIOVASCULAR AND NON-
CARDIOVASCULAR CAUSES. We also investigated
the relationship between preoperative HbA1c levels
and death from cardiovascular versus non-
cardiovascular causes. In a competing risk regression
analysis, we found that the subdistribution HRs for
death from cardiovascular and noncardiovascular
causes increased with increasing preoperative HbA1c
levels. However, because of the relatively low num-
ber of events, these risk estimates were not signiﬁ-
cant (Figure 2).
NONLINEAR RELATIONSHIP BETWEEN HBA1C AND
PROGNOSIS. We analyzed the potential nonlinear
relationship between HbA1c level and risk of death or
TABLE 1 Baseline Characteristics of 764 Patients With Type 1 Diabetes Who Underwent Primary Isolated Coronary Artery Bypass Grafting,
According to Baseline HbA1c Level
HbA1c #7.0,
67 (8.8%)
HbA1c 7.1–8.0,
190 (25%)
HbA1c 8.1–9.0,
296 (39%)
HbA1c 9.1–10.0,
146 (19%)
HbA1c >10.0,
65 (8.5%) p Value
Age, yrs 60.5  9.7 59.9  8.8 56.6  9.2 55.3  8.2 50.2  8.5 <0.001
Female 24 (35.8) 89 (46.8) 127 (42.9) 64 (43.8) 35 (53.8) 0.28
Body mass index, kg/m2 24.0  3.9 25.4  3.7 26.2  3.9 26.5  3.9 25.7  4.4 <0.001
eGFR <0.001
>60 ml/min/1.73 m2 36 (57.1) 109 (62.6) 178 (65.2) 87 (64.0) 29 (47.5)
45–60 ml/min/1.73 m2 8 (12.7) 26 (14.9) 44 (16.1) 17 (12.5) 4 (6.6)
30–45 ml/min/1.73 m2 6 (9.5) 11 (6.3) 16 (5.9) 17 (12.5) 13 (21.3)
15–30 ml/min/1.73 m2 0 (0.0) 10 (5.7) 5 (1.8) 4 (2.9) 4 (6.6)
End-stage renal disease 12 (17.9) 17 (8.9) 29 (9.8) 10 (6.8) 11 (16.9) 0.048
Duration, yrs 47.5  10.4 45.5  10.0 42.6  10.8 39.3  9.3 35.9  9.6 <0.001
Hypertension 30 (44.8) 76 (40.0) 134 (45.3) 55 (37.7) 27 (41.5) 0.57
Hyperlipidemia 12 (17.9) 46 (24.2) 83 (28.0) 40 (27.4) 22 (33.8) 0.26
Peripheral vascular disease 17 (25.4) 35 (18.4) 54 (18.2) 23 (15.8) 17 (26.2) 0.28
Earlier PCI 12 (17.9) 21 (11.1) 42 (14.2) 21 (14.4) 4 (6.2) 0.25
COPD 0 (0.0) 5 (2.6) 13 (4.4) 8 (5.5) 4 (6.2) 0.24
Earlier myocardial infarction 39 (58.2) 99 (52.1) 147 (49.7) 80 (54.8) 37 (56.9) 0.62
Heart failure 9 (13.4) 36 (18.9) 48 (16.2) 29 (19.9) 16 (24.6) 0.41
Stroke 6 (9.0) 21 (11.1) 33 (11.1) 20 (13.7) 8 (12.3) 0.87
Atrial ﬁbrillation 3 (4.5) 6 (3.2) 9 (3.0) 4 (2.7) 2 (3.1) 0.98
Left ventricular ejection fraction 0.23
>50% 32 (71.1) 88 (67.2) 141 (72.3) 63 (64.9) 21 (58.3)
30%–50% 9 (20.0) 38 (29.0) 44 (22.6) 29 (29.9) 15 (41.7)
<30% 4 (8.9) 5 (3.8) 10 (5.1) 5 (5.2) 0 (0.0)
EuroSCORE 3.7  2.9 3.8  2.4 3.3  2.6 3.2  2.3 3.6  1.9 0.22
Alcohol dependency 0 (0.0) 2 (1.1) 4 (1.4) 2 (1.4) 0 (0.0) 0.77
Birth region 0.015
Nordic countries 66 (98.5) 187 (98.4) 293 (99.0) 138 (94.5) 65 (100.0)
Other 1 (1.5) 3 (1.6) 3 (1.0) 8 (5.5) 0 (0.0)
Education 0.22
<10 yrs 23 (34.8) 56 (29.6) 97 (33.2) 50 (34.5) 20 (30.8)
10–12 yrs 29 (43.9) 87 (46.0) 135 (46.2) 66 (45.5) 40 (61.5)
>12 yrs 14 (21.2) 46 (24.3) 60 (20.5) 29 (20.0) 5 (7.7)
Marital status 0.024
Married 35 (52.2) 129 (67.9) 170 (57.4) 87 (59.6) 31 (47.7)
Other 32 (47.8) 61 (32.1) 126 (42.6) 59 (40.4) 34 (52.3)
Off-pump CABG 4 (6.0) 10 (5.3) 16 (5.4) 4 (2.7) 6 (9.2) 0.40
Number of grafts 0.048
1–2 13 (20.0) 20 (12.0) 55 (21.0) 22 (17.7) 9 (15.3)
3–4 46 (70.8) 129 (77.2) 171 (65.3) 80 (64.5) 36 (61.0)
>4 6 (9.2) 18 (10.8) 36 (13.7) 22 (17.7) 14 (23.7)
Type of graft
Internal mammary artery 60 (89.6) 182 (95.8) 280 (94.6) 137 (93.8) 62 (95.4) 0.42
Bilateral internal mammary arteries 0 (0.0) 0 (0.0) 2 (0.7) 5 (3.4) 1 (1.5) 0.024
Radial artery 3 (4.5) 7 (3.7) 11 (3.7) 4 (2.7) 5 (7.7) 0.54
More than 1 arterial graft 3 (4.5) 7 (3.7) 11 (3.7) 9 (6.2) 6 (9.2) 0.31
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate; HbA1c ¼ hemoglobin A1c;
PCI ¼ percutaneous coronary intervention.
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538MACE by entering HbA1c modeled with restricted cubic
splines in an age- and sex-adjusted Cox regression
model. As shown in the Central Illustration, a very small
risk increase was found in the HbA1c range from 6.0%
to 8.5%. However, a steep increase in the risk of deathor MACE was noted for each 1% increase in HbA1c level
>8.5%. When HbA1c was used as a continuous variable
in a Cox model adjusted for all variables shown in
Table 1, the HR for an absolute 1% increase in HbA1c
level was 1.18 (95% CI: 1.06 to 1.32; p ¼ 0.002).
FIGURE 1 Freedom From Death or MACE
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Age-adjusted freedom from death or major cardiovascular events
(MACE) in patients with type 1 diabetes who underwent primary
isolated coronary artery bypass grafting, according to baseline
hemoglobin A1c (HbA1c) level.
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539DISCUSSION
The main ﬁnding in this long-term (median, 4.7 years)
follow-up study was that high preoperative HbA1c
levels were signiﬁcantly associated with an increased
risk of death or MACE in patients with T1DM who
were undergoing primary isolated nonemergency
CABG in Sweden between 1997 and 2012. The associ-
ation between higher pre-operative HbA1c levels and
worse cardiovascular prognosis was independent of a
number of clinical characteristics and previously
identiﬁed risk factors. In patients with very poor
glycemic control, the risk of death or MACE was more
than twice that of patients with lower preoperative
HbA1c levels (<7.0%).
Chronic hyperglycemia affects several target
organs, including the heart, brain, and kidney, and
it contributes to organ damage. Although the devel-
opment of atherosclerosis is multifactorial, evidence
indicates that chronic hyperglycemia is a culprit inTABLE 2 Event Rates and Relative Risks for a Combination of All-Cau
Primary Isolated Coronary Artery Bypass Grafting in 764 Patients Wit
HbA1c Events/Person-Years
Rate per 1,000
Person-Years
(95% CI)
C
Hazard R
#7.0 (Ref) 29/358 81 (56–116)
7.1–8.0 76/993 76 (61–96) 0.92 (
8.1–9.0 122/1,588 77 (64–92) 0.94 (
9.1–10.0 64/796 80 (63–103) 0.98 (
>10.0 43/355 121 (90–163) 1.50 (
*A major adverse cardiovascular event was deﬁned as rehospitalization for myocardial in
was made for all variables in Table 1.
CI ¼ conﬁdence interval; HbA1c ¼ hemoglobin A1c; Ref ¼ reference category.macrovascular complications (22). Coronary atheroma
is more common among diabetic patients, and HbA1c
level is associated with progression of atherosclerosis
and CHD (23). In the follow-up of patients with T1DM
in the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Control, intensive glycemic
control reduced the risk of CVD events (24). Recent
epidemiological data also support a relationship be-
tween hyperglycemia and CVD mortality in patients
with T1DM (5,25–28). CVD events occur as much as 10
to 15 years earlier in patients with T1DM compared
with nondiabetic patients (6). In our study, there was
a robust association between preoperative HbA1c
levels and all-cause mortality or MACE that conﬁrmed
hyperglycemia as a major risk factor in T1DM. Chronic
hyperglycemia is generally thought to be the most
important modiﬁable risk factor for long-term com-
plications in T1DM (29). As HbA1c rises, other risk
factors for CVD events also tend to increase. Blood
pressure, hyperlipidemia, body mass index, and renal
failure can all modify the risk of CVD events. Age, sex,
and diabetes duration are additional risk factors for
CVD events. After adjustment for age and sex, pa-
tients with poor glycemic control and high HbA1c
levels had a signiﬁcantly higher risk of death or
MACE. Multivariable adjustment for a number of
other risk factors did not attenuate the HRs for death
or MACE. In fact, the relationship between HbA1c
level and death or MACE was already signiﬁcant at
HbA1c levels of 7.1% to 8.0%, and it increased further
by 18% for every 1% absolute increase in HbA1c levels.
In a recent large study from the Swedish National
Diabetes Register, patients with T1DM, even those
with very good glycemic control (HbA1c <6.9%), had
more than double the risk of death compared with the
general population. This risk increased further for
every 1% absolute increase in HbA1c level, with a more
than 5-fold increased risk of death from cardiovas-
cular causes in patients with the highest HbA1c levels
(5). Patients in our study all had manifest severe CHD,se Mortality or Major Adverse Cardiovascular Events* After
h Type 1 Diabetes, According to Baseline HbA1c
rude
atio (95% CI)
Age- and
Sex-Adjusted
Hazard Ratio (95% CI)
Multivariable Adjusted†
Hazard Ratio (95% CI)
1.00 1.00 1.00
0.60–1.41) 1.10 (0.71–1.71) 1.34 (0.82–2.21)
0.63–1.42) 1.23 (0.81–1.87) 1.59 (1.00–2.54)
0.63–1.53) 1.34 (0.85–2.11) 1.73 (1.03–2.90)
0.94–2.40) 2.23 (1.36–3.66) 2.25 (1.29–3.94)
farction, heart failure, stroke, or repeat revascularization. †Multivariable adjustment
CENTRAL ILLUSTRATION HbA1c and Prognosis After CABG in Type 1 Diabetes
Nyström, T. et al. J Am Coll Cardiol. 2015; 66(5):535–43.
This ﬁgure shows the relationship (event rates and adjusted relative risks for the association) between pre-operative hemoglobin A1c (HbA1c) level
(in clinically relevant categories above and also as a continuous variable below) and all-cause mortality or a major cardiovascular event (MACE). The graph
shows the adjusted hazard ratio (solid salmon line) and 95% conﬁdence intervals (dashed blue lines) for the association between baseline HbA1c and
combined all-cause mortality and major cardiovascular event occurrence. The baseline HbA1c level was modeled with restricted cubic splines with 3
knots (at 7.1%, 8.5%, and 9.8%) in a Cox regression model. The reference level was set at 7.0% for the estimation of hazard ratios. The Cox model was
adjusted for age and sex. The main ﬁnding of our study was that higher preoperative HbA1c levels were signiﬁcantly associated with an increased risk
of death or MACE in patients with type 1 diabetes who underwent coronary artery bypass grafting. CI ¼ conﬁdence interval; PY ¼ person-years;
Ref ¼ reference category.
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540they were old, and they had diabetes of long duration.
These patients were therefore at high risk for death or
MACE, as conﬁrmed by the high incidence of these
outcomes, an incidence higher than that reported in
another recently published study (30). However, in
that study, no distinction was made between the
types of diabetes. Patients with earlier CHD have an
increased incidence of new CVD events. Patients
with type 2 diabetes mellitus (T2DM) have the same
increased risk of myocardial infarction as nondiabeticpatients who have had an earlier myocardial infarc-
tion (31). Findings of this 1998 index study resulted
in the recommendation that patients with T2DM
should be regarded as CHD equivalent (31). Intensi-
ﬁed intervention against multiple risk factors in pa-
tients with T2DM strongly reduces the risk of CVD
events (32). Whether this reduced risk is seen in pa-
tients with T1DM is not fully understood (4). Standard
CHD risk factors (e.g., lipids, blood pressure, and
obesity) are clearly operational in T1DM. However,
FIGURE 2 Incidence Rate and Relative Risks According to Baseline HbA1c
Outcome
Death+MACE
CV death
Non-CV death
No. events/PY Crude rate [95% CI]
per 1,000 PY
Adjusted hazard ratio
[95% CI]
≤7.0 (Ref)
7.1-8.0
29/358 81 [56 - 116] 1.00
1.34 [0.82 - 2.21]
1.59 [1.00 - 2.54]
1.73 [1.03 - 2.90]
2.25 [1.29 - 3.94]
1.00
1.46 [0.56 - 3.78]
1.62 [0.64 - 4.13]
1.32 [0.46 - 3.79]
2.15 [0.73 - 6.32]
1.00
1.09 [0.48 - 2.46]
1.46 [0.68 - 3.16]
1.55 [0.70 - 3.45]
2.13 [0.85 - 5.34]
0.5 1 1.5 2 2.5 3 3.5 4
76 [61 - 96]
77 [64 - 92]
80 [63 - 103]
121 [90 - 163]
19 [9.7 - 39]
20 [13 - 30]
19 [13 - 26]
13 [7.7 - 23]
25 [14 - 45]
22 [11 - 42]
18 [12 - 28]
20 [14 - 27]
21 [14 - 33]
34 [21 - 57]
76/993
122/1,588
64/796
43/355
8/411
13/982
11/440
9/411
21/982
15/440
21/1,167
37/1,871
23/1,167
35/1,871
8.1-9.0
9.1-10.0
>10.0
≤7.0 (Ref)
7.1-8.0
8.1-9.0
9.1-10.0
>10.0
≤7.0 (Ref)
7.1-8.0
8.1-9.0
9.1-10.0
>10.0
Crude incidence rates and adjusted hazard ratios for 3 outcomes: 1) combined all-cause mortality and major adverse cardiovascular events; 2)
cardiovascular death; and 3) noncardiovascular death, in patients with type 1 diabetes who underwent primary isolated coronary artery bypass
grafting, according to baseline HbA1c level. Hazard ratios for cardiovascular (CV) death and non-CV death are subdistribution hazard ratios from
competing risk regression models that were adjusted for age, sex, left ventricular ejection fraction, and renal function. PY ¼ person-years;
Ref ¼ reference category.
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541management approaches to CHD reduction have been
extrapolated from T2DM studies and are therefore not
easily applied to patients with T1DM. In the present
study, HRs did not change after adjustments for well-
known CVD risk factors, including chronic kidney
disease, a ﬁnding suggesting glycemic control as the
most important risk factor for death or MACE.
A recent study examined whether preoperative
HbA1c levels can help predict mortality and morbidity
after CABG (11). Some studies (33–35), but not all
(36–38), have demonstrated an association between
HbA1c levels and CVD outcome in patients after CABG.
Earlier studies that examined the impact of preoper-
ative HbA1c as a risk factor for long-term mortality
after CABG (39,40) found that patients with
HbA1c higher than 7% had lower 5-year survival
compared with patients with HbA1c lower than 7%.
After adjustment, higher HbA1c was associated with
reduced long-term survival (39). Recently, it was also
demonstrated that HbA1c levels predict insulin
sensitivity during cardiac surgical procedures andpossibly outcome in diabetic patients (41). However,
none of these studies (39–41) distinguished between
T1DM and T2DM. Studies investigating the prognostic
impact of diabetes in patients after CABG are even
more ambiguous (7–10). Results from these studies
have been conﬂicting, demonstrating either an asso-
ciation with adverse outcome (9) or no association
with outcome (8). Importantly, categorization into
T1DM and T2DM in these studies is lacking (8,9). To
the best of our knowledge, only one study categorized
CABG-treated patients into T1DM and T2DM. In that
study, the investigators found an increased risk of
death or myocardial infarction for both T1DM and
T2DM (42). However, that study was conducted more
than 3 decades ago, and considering that the risks of
death and CVD events associated with diabetes
have been reduced by more than one-half during the
last 2 decades (2), those results should be interpreted
with caution in a contemporary population. Our ﬁnd-
ings are in line with those of a recent study of dia-
betic patients who underwent percutaneous coronary
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Although CABG surgical
intervention is the preferred method of revasculari-
zation for patients with diabetes and multivessel
coronary artery disease, patients with T1DM who had
poor glycemic control before CABG faced risks of
death or MACE over the ensuing 5 years that were
more than twice as high as risks in patients with T1DM
who had adequate glycemic control.
TRANSLATIONAL OUTLOOK: Interventions to
achieve better control of blood glucose concentra-
tions and other cardiovascular risk factors in patients
with T1DM should be evaluated in prospective trials.
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542intervention procedures and were categorized ac-
cording to HbA1c levels. Patients with poor glycemic
control had higher long-term mortality than did pa-
tients with good glycemic control (HbA1c <7.0%) (28).
In that study, there was no attempt to distinguish be-
tween types of diabetes; therefore, the results cannot
be translated to patients with T1DM (28).
This study investigated the incidence of death and
MACE in T1DM patients after CABG. The information
used to categorize patients as T1DM has been shown
to have a high validity (43). Other strengths of this
study were its nationwide population-based design,
the long follow-up period, and the accurate determi-
nation of mortality and MACE because of the high-
quality national Swedish health data registers.
STUDY LIMITATIONS. We lacked information re-
garding CVD medications and insulin doses. Within
the scope of this study, we cannot rule out the role of
underlying microvascular complications. However,
we considered estimated glomerular ﬁltration rate as
a proxy for microvascular disease, which could be
controlled for in the multivariable models. As in any
observational study, we cannot rule out that residual
confounding factors affected our ﬁndings.
CONCLUSIONS
Our study found that patients with T1DM who were
undergoing CABG were at high risk for death or MACE
during a median follow-up period of 4.7 years, and we
also found that elevated preoperative HbA1c levels
were signiﬁcantly associated with an increased risk
for all-cause mortality or MACE. In patients withT1DM with very poor glycemic control before CABG,
the long-term risk of death or MACE was more than
double that in patients with T1DM who had adequate
glycemic control.
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